Connect with us

International

Five Mid-Cap Pharmaceutical Investments to Purchase 

Five mid-cap pharmaceutical investments to purchase present three high-potential stocks and two exchange-traded funds, despite Russia’s war in Ukraine,…

Published

on

Five mid-cap pharmaceutical investments to purchase present three high-potential stocks and two exchange-traded funds, despite Russia’s war in Ukraine, inflation and recession risk.

The five mid-cap pharmaceutical investments to purchase focus on stocks that have the prospect of becoming large-cap companies of $10 billion and up. Mid-cap stocks, defined by the Financial Industry Regulatory Authority (FINRA) as those with a market cap of $2 billion to $10 billion, tend to grow at faster rates than industry giants since their smaller size magnifies the impact of gains.

Investors who want a diversified portfolio of pharmaceuticals, including biopharmaceuticals, can choose among several ETFs, said Bob Carlson, a pension fund chairman and also leads the Retirement Watch investment newsletter. Carlson said he likes the simplicity of choosing funds for investors seeking exposure to an array of drug company stocks of various sizes, including mid-caps.

Retirement Watch head Bob Carlson discusses investing with Paul Dykewicz.

Five Mid-Cap Pharmaceutical Investments to Purchase

Another seasoned investment professional who has successfully invested in pharmaceutical stocks is Mark Skousen, PhD, who recommended a profitable one in his Forecasts & Strategies investment newsletter as the overall market struggled during the pandemic. The dividend-paying stock rose 54.76% from December 2015 to July 2021, including part of the pandemic.

One of the challenges in investing in pharmaceutical stocks is entering and exiting at the right times, since new product development is not guaranteed to succeed. Skousen chose a large-cap stock and held it through the first part of the COVID-19 pandemic.  

The stock, New York-based Pfizer Inc. (NYSE: PFE), proved to be a strong investment when it astutely teamed up with a smaller industry partner, BioNTech SE (NASDAQ: BNTX), a Mainz, Germany-based biotechnology company that has grown beyond the mid-cap stage and now is at the low end of the large-cap range with a market cap of $31.31 billion. Even though Pfizer did not acquire BioNTech, the two companies formed a partnership to provide one of the first and most effective COVID-19 vaccines in the world.

BioNTech was a mid-cap stock as recently as 2019, when it had a market cap of $7.68 billion before the pandemic. It then formed a partnership with Pfizer to lead the industry in producing and distributing an effective vaccine. The share prices of BioNTech and Pfizer both rose during the pandemic but Skousen, who also leads the Five Star Trader advisory service that features stocks and options, identified weakness developing in the stocks and the market when he instructed his subscribers to take profits. Skousen also tracks inflation and recession risk closely.

Mark Skousen, a scion of Ben Franklin and head of Five Star Trader, meets Paul Dykewicz.

Xenon is One of Five Mid-Cap Pharmaceutical Investments to Purchase

Vancouver, Canada-based Xenon Pharmaceuticals Inc. (NASDAQ: XENE), with a market capitalization of $2.272 billion, is a clinical stage biopharmaceutical company that is developing therapeutics to improve the lives of patients with neurological disorders. Xenon is rated to “outperform” the market by the Chicago-based William Blair investment banking and wealth management firm.

The investment firm assigned an estimated fair value of $47 per share to Xenon, based on a risk-adjusted net present value of the company’s key products sold in the United States and the European Union. The company’s niche is to provide a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.

With a significantly differentiated selective “voltage-gated ion channel modulator platform,” de-risked mechanisms of action for generalized antiseizure medications (ASMs) and a targeted therapy approach for pediatric EEs, Xenon is positioned as a potential market leader in that pediatric treatment, as well as a possible large provider in the broad epilepsy market.

Chart courtesy of www.stockcharts.com

Xenon improved its cash position in June 2022 with a public offering that boosted its cash, cash equivalents and marketable securities to $720.8 million at year-end 2022, compared to $551.8 million at the end of 2021. Based on current operating plans, including the completion of the XEN1101 Phase 3 epilepsy studies, Xenon management estimated having sufficient cash to fund operations into 2026.

The company reported no revenue in fourth-quarter 2022 and $9.4 million for full-year 2022, compared to $3.7 million and $18.4 million for the same periods in 2021, respectively. For 2022, the decrease of $9.0 million was primarily due to the Neurocrine Biosciences collaboration; all performance obligations associated with an upfront payment were completed in March 2022 and the research component of the collaboration ended in June 2022. In addition, $3.0 million was recognized under an agreement with Pacira BioSciences in the year ended 2021, whereas the agreement did not result in any revenue for the year ended 2022.

“Prescribing physicians are seeking new, differentiated therapeutic options that improve upon existing anti-seizure medications, and we remain committed to improving the lives of patients with epilepsy,” said Ian Mortimer, Xenon’s president and chief executive officer. “We look forward to important clinical milestones this year including the anticipated topline read-out in the third quarter from our XEN1101 Phase 2 X-NOVA study in major depressive disorder as well as an anticipated data read-out from our partners at Neurocrine from their Phase 2 study in adult patients with focal onset seizures in the second half of the year.”

Five Mid-Cap Pharmaceutical Investments to Purchase Include CRISPR Therapeutics

Zug, Switzerland-based CRISPR Therapeutics AG (NASDAQ: CRSP) is a mid-cap stock with $3.762 billion market capitalization. William Blair gave CRISPR Therapeutics an “outperform” rating, adding that the company has shown initial proof of concept for intransfusion-dependent beta thalassemia (TDT), sickle cell disease (SCD) and its wholly owned immuno-oncology platform, de-risking the ex vivo use of its technology.

In addition, CRISPR Therapeutics has executed on the licensing of its platform in noncore indications for nondilutive capital, William Blair wrote in a recent research note. Given the optionality of the CRISPR-Cas9 platform and potential cost-effectiveness compared with lentiviral-based therapies, William Blair wrote that the company could be a potential takeout candidate for the right acquirer.

CRISPR Therapeutics reported fourth-quarter earnings and provided a corporate update on Feb. 21. CRISPR, with its partner Vertex (NASDAQ: VRTX), completed regulatory submissions with the European Union and United Kingdom for exa-cel (CTX001) in the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in late 2022. Both the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have validated the related marketing authorization application. The companies expect to complete the submission of their rolling BLA filing in the United States by the end of the first quarter of 2023. 

Chart courtesy of www.stockcharts.com

Five Mid-Cap Pharmaceutical Investments to Purchase Include Rising Small Cap

Tustin, California-based Avid Bioservices (CDMO), with a market cap of $1.01 billion, is a contract development and manufacturing organization, or a CDMO. It explains why the company’s leaders chose CDMO as the stock’s ticker symbol, said Michelle Connell, head of Dallas-based Portia Capital Management

Avid provides manufacturing facilities to other biotech companies, since the industry is constrained and is “very short” on capacity. To address the problem, Avid is in the process of more than doubling its capacity, Connell continued. 

Michelle Connell leads Dallas-based Portia Capital Management.

A reason Connell said she prefers CDMO to other biotech companies is that it is not developing pharmaceuticals and thereby is not dependent on Food and Drug Administration (FDA) approval, Connell counseled. Biotech companies that are dependent upon FDA approval are binary, either winning or losing, she added.

“Thus, there can be huge risk owning one or two pure biotech plays,” Connell said.

Last quarter, CDMO failed to meet its earnings estimates. However, since Avid is building out capacity, the company’s management remains very optimistic, she added.

Avid increased its guidance for future quarters when it missed its latest earnings, Connell continued. She further pointed out that, unlike many biotech plays, Avid is profitable in terms of net income and cash flow. Even though the stock is not quite big enough to reach the low end of the mid-cap category, Connell said she likes it well enough to rate the rising small cap as top choice in both groups.

“Its operating cash flow has been positive for the past three years,” Connell said. “Like most biotechnology stocks, Avid had negative performance in 2022. However, this year the stock is up over 20%. As the company is still cheap on a price-to-earnings as well as price-to-sales basis, I believe the stock has additional upside of 10 to 20% in the next 12 months.”

Chart courtesy of www.stockcharts.com

Connell counseled not to buy a full investment position in Avid in any rush, since its earnings are expected on March 9. 

“I think there will be opportunities to add to positions after this earnings announcement,” Connell said.

ETF Is One of Five Mid-Cap Pharmaceutical Investments to Purchase for Safety

First Trust Nasdaq Pharmaceuticals (FTXH) has earned higher returns over time compared to the alternative ETF, but it is the more volatile of the two choices, Carlson said. The fund generally holds smaller companies that are trading at lower valuations, compared to the portfolios of competing pharmaceutical ETFs, he added.

“As a result, the companies owned by the fund tend to have lower dividends and stock buybacks than others in the industry,” Carlson said.

In addition, FTXH is a concentrated fund that recently held 30 positions and had 58% of the portfolio in the 10 largest positions. The portfolio can change rapidly, with the ETF having a 77% turnover rate in the last year, Carlson counseled.

Top holdings recently were Merck & Co. (NYSE: MRK), Gilead Sciences (NASDAQ: QILD), Bristol-Meyers Squibb (NYSE: BMY), Johnson & Johnson (NYSE: JNJ) and Amgen (NASDAQ: AMGN). The fund had a 2.55% return in 2022.

Chart courtesy of www.stockcharts.com

Five Mid-Cap Pharmaceutical Investments to Purchase as Protection Include IHE

A more conservative choice than FTXH is iShares U.S. Pharmaceuticals (IHE). The fund aims to track the Dow Jones U.S. Select Pharmaceuticals Index. Because it tries to mirror an index, IHE has a much lower turnover ratio of only 20% compared to FTXH.

IHE recently had 48 positions and 74% of its portfolio was composed of its 10 largest positions. Top holdings were Johnson & Johnson, Eli Lilly (NYSE: LLY), Catalent (NYSE: CTLT), Zoetis (NYSE: ZTS) and Viatris (NASDAQ: VTRS).

The fund declined 4.87% in 2022 and is down 6.05% so far this year.

Chart courtesy of www.stockcharts.com

Micro-Cap Pharmaceutical Stocks Offer Alternative Way to Invest

Another way to invest in biopharmaceuticals is through micro-cap stocks. That is the niche of futurist George Gilder’s Moonshots advisory service, which intentionally limits its circulation to enhance its exclusivity. The Moonshots track record has been shining as an outperforming advisory service that may have a new pharmaceutical pick soon after Gilder and Senior Analyst Richard Vigilante recently returned from a trip to Israel to conduct due diligence on potential investments.

My column next week will feature mid-cap pharmaceutical stocks, but investors interested in micro-cap alternatives may want to know Moonshots’ portfolio companies jumped an average of 84%, double the gains of the NASDAQ, from July 2019 to February 2023, counting only closed positions. I am trying to obtain direct input from Gilder and his team next week as they seek out companies developing the kinds of new paradigms that investors crave.

Wagner Mercenary Boss Blames Russia for Not Providing Enough Ammunition

The head of Russia’s Wagner private army complained that his soldiers are not receiving the needed ammunition to gain control of Bakhmut, a fiercely contested city in eastern Ukraine. Wagner’s leader Yevgeny Prigozhin was quoted as saying his army’s inadequate ammunition supply could be bureaucracy or a ‘betrayal.”

Russian forces have not managed to surround the city, Ukrainian officials said. Civilians there reportedly number in the thousands and are mostly cut off from humanitarian relief.

Russia has absorbed more combat deaths in Ukraine during its first year of war than in all its wars combined since the end of World War II, according to research from the Center for Strategic and International Studies (CSIS). The average number of Russian troops killed per month is 25 times the number per month in Chechnya and 35 times those killed in Afghanistan.

“The Ukrainian military has also performed remarkably well against a much larger and initially better-equipped Russian military, in part due to the innovation of its forces,” the CSIS wrote.

Xi Voices Hostility After FBI Chief Says COVID-19 Likely Came from Lab in China

China’s leader, Xi Jinping, and his new Foreign Minister Qin Gang accused U.S. leaders in recent days of suppressing China’s development and creating conflict between the two countries. The criticism came after FBI Director Christopher Wray said on Tuesday, Feb. 28, that COVID-19 likely leaked out of a laboratory in China. It marked the first public opinion of that kind from the FBI about the origins of the virus that caused a global pandemic.

“The FBI has for quite some time now assessed that the origins of the pandemic are most likely a potential lab incident in Wuhan,” Wray told Fox News. “Here you are talking about a potential leak from a Chinese government-controlled lab.”

Worldwide COVID-19 deaths rose to 6,878,624 people, with total cases of 676,202,710, Johns Hopkins University reported on March 7. COVID-19 cases in the United States totaled 103,680,242, while deaths reached 1,122,599 as of March 7, according to Johns Hopkins University. Until recent reports that China had more than 248 million cases of COVID-19, America had ranked as the nation with the most coronavirus cases and deaths.

The U.S. Centers for Disease Control and Prevention reported that 269,554,116 people, or 81.2% of the U.S. population, have received at least one dose of a COVID-19 vaccine, as of March 1. People who have completed the primary COVID-19 doses totaled 230,075,934 of the U.S. population, or 69.3%, according to the CDC. The United States has given a bivalent COVID-19 booster to 50,544,428 people who are age 18 and up, equaling 19.6% as of March 1.

The five mid-cap pharmaceutical investments to purchase for safety offer opportunities that seem insulated from the ravages of Russia’s ongoing invasion of Ukraine and elevated inflation and recession risk. Pharmaceutical investments may offer a formula for investors to gain exposure to companies that provide medications that are needed regardless of war.

Paul Dykewicz, www.pauldykewicz.com, is an accomplished, award-winning journalist who has written for Dow Jones, the Wall Street JournalInvestor’s Business DailyUSA Today, the Journal of Commerce, Seeking Alpha, Guru Focus and other publications and websites. Paul, who can be followed on Twitter @PaulDykewicz, is the editor of StockInvestor.com and DividendInvestor.com, a writer for both websites and a columnist. He further is editorial director of Eagle Financial Publications in Washington, D.C., where he edits monthly investment newsletters, time-sensitive trading alerts, free e-letters and other investment reports. Paul previously served as business editor of Baltimore’s Daily Record newspaper. He is the author of an inspirational book, “Holy Smokes! Golden Guidance from Notre Dame’s Championship Chaplain,” with a foreword by former national championship-winning football coach Lou Holtz. The uplifting book is great gift and is endorsed by Joe Montana, Joe Theismann, Ara Parseghian, “Rocket” Ismail, Reggie Brooks, Dick Vitale and many othersCall 202-677-4457 for special pricing on multiple-book purchases.

The post Five Mid-Cap Pharmaceutical Investments to Purchase  appeared first on Stock Investor.

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

International

Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.

Published

on

Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 

Shutterstock

This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading

Trending